

□

**GLOBANT S.A.**

**37A, Avenue J.F. Kennedy, L-1855, Luxembourg  
RCS Luxembourg: B 173727**

The undersigned hereby appoints the Chairman of the General Meetings as proxy, with full power of substitution, to represent and vote as designated on the reverse side, all of the common shares of Globant S.A. held of record by the undersigned at 24 o'clock Luxembourg Time on April 9, 2024, at the Annual General Meeting and the Extraordinary General Meeting of Shareholders to be held at the Company's registered office on May 10, 2024 and at any adjournments or postponements thereof. Should a quorum not be reached at the Extraordinary General Meeting of Shareholders, this proxy shall remain valid for a second Extraordinary General Meeting of Shareholders to be convened with the same agenda unless expressly revoked. This proxy is governed by Luxembourg law. Any disputes arising out of, or in connection with, this proxy shall be submitted exclusively to the courts of the city of Luxembourg, Grand Duchy of Luxembourg.

**(Continued and to be signed on the reverse side)**

ANNUAL GENERAL MEETING AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF

# GLOBALANT S.A.

May 10, 2024

**GO GREEN**

e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via <https://equiniti.com/us/ast-access> to enjoy online access.

**NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL:**

The convening notice and proxy card are available at [www.globant.com](http://www.globant.com)

**E-MAIL** - Completed proxy cards may be sent via email as a PDF attachment to Equiniti Trust Company, LLC at the following email addresses: [proxy@equiniti.com](mailto:proxy@equiniti.com) and [admin3@equiniti.com](mailto:admin3@equiniti.com). Please be sure to send your completed proxy card via PDF to both of the email addresses provided and to use the subject line: "Globant Proxy Card".

**MAIL** - Sign, date and mail your proxy card in the envelope provided as soon as possible.

**IN PERSON** - You may vote your shares in person by attending the General Meetings.

↓ Please detach along perforated line and mail in the envelope provided. ↓

051024

**THE BOARD OF DIRECTORS (OR THE RELEVANT BOARD COMMITTEE) RECOMMENDS A VOTE "FOR" RESOLUTIONS 2-13 OF THE ANNUAL GENERAL MEETING AND RESOLUTION 1 OF THE EXTRAORDINARY GENERAL MEETING**  
**PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE OR BY E-MAIL. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE**

*The undersigned acknowledges receipt of the Convening Notice from the Company in advance of the execution of this proxy.*

MARK "X" HERE IF YOU PLAN TO ATTEND THE GENERAL MEETINGS.

(Option available only until 24 o'clock Luxembourg Time on May 3, 2024)

If amendments or new resolutions are presented at the General Meetings, I irrevocably give the Chairman of the General Meetings the power to vote in my name and as he or she deems fit unless I mark the box below:

I abstain:

To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

**RESOLUTIONS OF THE ANNUAL GENERAL MEETING:**

	NO VOTE REQUIRED		
	FOR	AGAINST	ABSTAIN
1. Presentation of the reports of the independent auditor and of the reports of the Board of Directors of the Company on the consolidated accounts for the financial year ended on December 31, 2023 and on the annual accounts of the Company for the financial year ended on December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Approval of the consolidated accounts of the Company prepared under EU IFRS and IFRS as of and for the financial year ended December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Approval of the Company's annual accounts under LUX GAAP as of and for the financial year ended December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Allocation of results for the financial year ended December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Vote on discharge (quitus) of the members of the Board of Directors for the proper exercise of their mandate during the financial year ended December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Approval and ratification of the share-based compensation granted to a certain non-executive member of the Board of Directors during the financial year ending on December 31, 2023.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Approval of the cash and share-based compensation payable to the non-executive members of the Board of Directors for the financial year ending on December 31, 2024.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Appointment of PricewaterhouseCoopers, Société coopérative, as independent auditor for the annual accounts and the EU IFRS consolidated accounts of the Company for the financial year ending on December 31, 2024.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Appointment of Price Waterhouse & Co. S.R.L. as independent auditor for the IFRS consolidated accounts of the Company for the financial year ending on December 31, 2024.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Re-appointment of Mr. Martín Migoya as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2027.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Appointment of Mr. Andrew McLaughlin as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2027.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Appointment of Mr. Alejandro Nicolás Aguzin as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2027.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Renewal of the authorization granted to the Board of Directors, according to article 430-15 of the law of 10 August 1915 on commercial companies, as amended, to repurchase during a five-year period ending on the fifth (5th) anniversary of this Annual General Meeting of Shareholders, a maximum number of common stock representing twenty percent (20%) of the issued share capital of the Company, for a net purchase price that is (i) no less than fifty percent (50%) of the lowest common stock price and (ii) no more than fifty percent (50%) above the highest common stock price, in each case, such common stock price being the closing price reported by the New York City edition of the Wall Street Journal, or, if not reported therein, any other authoritative source to be selected by the Board of Directors, over the ten (10) trading days preceding the date of the purchase (or as the casemay be, the date of the commitment to the transaction).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**RESOLUTION FOR THE EXTRAORDINARY GENERAL MEETING:**

1. Approval of the increase in the authorized capital of the Company and subsequent amendment to the Articles of Association.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
---	--------------------------	--------------------------	--------------------------

Signature of Shareholder  Date:  Signature of Shareholder  Date:

**Note:** Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.